Trial
NCT05327738
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
Condition
BCLC Stage B Hepatocellular Carcinoma
Intervention
Atezolizumab
Why stopped
Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending drug approval.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-14